- Home
- AGIO
as 10-07-2025 3:29pm EST
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.4B | IPO Year: | 2013 |
| Target Price: | $57.25 | AVG Volume (30 days): | 577.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 11.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.41 - $62.58 | Next Earning Date: | 10-30-2025 |
| Revenue: | $40,875,000 | Revenue Growth: | 30.57% |
| Revenue Growth (this year): | 23.76% | Revenue Growth (next year): | 148.23% |
Stock Insider Trading Activity of Agios Pharmaceuticals Inc. (AGIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Scadden David | AGIO | Director | Sep 30 '25 | Sell | $40.00 | 200 | $8,000.00 | 17,603 | |
| Jones Cecilia | AGIO | Chief Financial Officer | Sep 26 '25 | Sell | $36.77 | 3,651 | $134,247.27 | 33,870 | |
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Sep 5 '25 | Sell | $36.87 | 8,546 | $315,091.02 | 868 | |
| Scadden David | AGIO | Director | Aug 27 '25 | Sell | $40.00 | 200 | $8,000.00 | 17,603 | |
| Goff Brian | AGIO | Chief Executive Officer | Aug 8 '25 | Sell | $36.67 | 11,085 | $406,486.95 | 123,528 |
Latest Agios Pharmaceuticals Inc. News
AGIO Breaking Stock News: Dive into AGIO Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer
Simply Wall St.
a month ago
FDA Review Delay for PYRUKYND Might Change the Case for Investing in Agios Pharmaceuticals (AGIO)
Zacks
a month ago
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
MT Newswires
3 months ago
Agios Pharmaceuticals Insider Sold Shares Worth $627,198, According to a Recent SEC Filing
Insider Monkey
4 months ago
Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential
Insider Monkey
4 months ago
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT
Zacks
4 months ago
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
Zacks
4 months ago
Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?
Compare AGIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGIO Agios Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.